Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR

Caitlin J Harrigan1, Dana C Peters, C Michael Gibson

  • 1PERFUSE Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center, Harvard Medical School, RW 453 East Campus, 330 Brookline Ave, Boston, MA 02215, USA.

Radiology
|November 4, 2010
PubMed

Insights

The 6 SD gray-scale threshold best quantifies late gadolinium enhancement (LGE) in hypertrophic cardiomyopathy (HCM) patients, offering high reproducibility. This semiautomated method improves accuracy for LGE assessment in HCM.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Biomedical Engineering

Background:

  • Hypertrophic cardiomyopathy (HCM) is a significant cause of sudden cardiac death.
  • Accurate quantification of late gadolinium enhancement (LGE) in HCM is crucial for risk stratification.
  • Current LGE quantification methods can lack reproducibility.

Purpose of the Study:

  • To identify the most reproducible semiautomated gray-scale thresholding technique for quantifying LGE in HCM patients.
  • To compare the accuracy and reproducibility of different thresholding methods against visual assessment.

Main Methods:

  • 201 patients with HCM underwent LGE cardiovascular magnetic resonance (MR) imaging.
  • LGE was quantified using visual assessment and semiautomated gray-scale thresholds (2, 4, 6 SDs above mean, 2 SDs above noise).
  • Reproducibility was assessed by repeating measurements and using Bland-Altman analysis and correlation coefficients.

Main Results:

  • The 6 SD threshold showed the strongest correlation (r=0.913) with visual LGE assessment.
  • This method demonstrated significantly less intraobserver (0.6 g ± 8) and interobserver (5.4 g ± 18) variability compared to visual assessment.
  • All tested gray-scale thresholds correlated significantly with visual assessment.

Conclusions:

  • Semiautomated LGE quantification using a 6 SD threshold above the mean signal intensity is a reproducible and accurate method for HCM.
  • This objective approach closely approximates visual assessment of LGE extent.
  • The 6 SD threshold method is recommended for quantifying LGE in clinical practice for HCM patients.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...